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Purpose
There are three classes of HIV-1 based on diversity of
the viral envelope: M (major), O (outlying) and N (new).
The M group is subclassified into nine major subtypes
including A—D, F—H, J and K, as well as several
recombinant forms. There is a growing need to evaluate
antiretroviral (ARV) treatment in these diverse subtypes.
Methods
M06-802 was an open-label, global, 48-week phase III
trial. 599 ARV-experienced, HIV-1-infected subjects
were randomized 1:1 to receive LPV/r 800/200mg QD
or 400/100mg BID with ≥2 investigator-selected nucleo-
side/nucleotide reverse transcriptase inhibitors. Classifi-
cation of HIV-1 viruses by subtype was determined by
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Figure 1 Percent of subjects infected with different subtypes that have plasma HIV-1 RNA <50 copies/mL, FDA-TLOVR analysis
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analysis.
Results
Of the 595 subjects with available sequence data, 386
(65%) were infected with subtype B, 121 (20%) were
infected with subtype C, 88 (15%) were infected with
another subtype. Subjects infected with subtype B were
more likely to be male (75%), white (56%), and living in
North America (N.A.) (52%), while subjects infected
w i t hs u b t y p eCw e r em o r el i k e l yt ob ef e m a l e( 5 6 % ) ,
black (83%), and living outside of N.A. or Western Eur-
ope (W.E.) (99%). Subjects infected with other subtypes
were more likely to be male (56%), white (88%) and liv-
ing outside of N.A. or W.E. (82%). The proportion of
subjects with subtype B responding to treatment at
week 48 as analyzed using the FDA-TLOVR method
(53%) was similar to that of subtype C subjects (57%,
P=0.465) and non-B subtype subjects (55%, P=0.731)
( F i g u r e1 ) .T h ep r e v a l e n c eo fm o d e r a t e / s e v e r et r e a t -
ment-related adverse events was similar across subtypes.
There was a nonsignificant trend to more frequent
emergence of new protease resistance mutations in sub-
type B (18%) vs. subtype C (8%, P=0.277) or non-B (7%,
P=0.088) subjects; however, subtype B subjects were
more likely to have previously been treated with PIs.
Conclusion
LPV/r demonstrated similar efficacy and safety among
subjects infected with different HIV-1 subtypes.
Published: 8 November 2010
doi:10.1186/1758-2652-13-S4-P30
Cite this article as: Maroldo et al.: Efficacy and safety of lopinavir/
ritonavir (LPV/r) in antiretroviral-experienced subjects infected with
different subtypes of HIV-1. Journal of the International AIDS Society 2010
13(Suppl 4):P30.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Maroldo et al. Journal of the International AIDS Society 2010, 13(Suppl 4):P30
http://www.jiasociety.org/content/13/S4/P30
Page 2 of 2